HKSE:2269

WuXi Biologics (Cayman) Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 12:11 UTC

Last close

n/aHKD

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

34.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
12.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
22.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
12.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.25 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.23x

2.12x

-4.11x

0.89x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales2.23x
Its own average over 10 years, 9.78B.
Profit2.12x
Its own average over 10 years, 2.32B.
Free cash flow-4.11x
Its own average over 10 years, -680.8M.
Debt0.89x
Its own average over 8 years, 3.50B.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -4.11 times.

It reports in CNY and trades in HKD. Nothing on this page is converted between the two.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2016-12-31	100.0	100.0	100.0
2017-12-31	163.7	179.0	102.3
2018-12-31	256.3	446.9	115.8
2019-12-31	402.8	718.5	117.5
2020-12-31	567.5	1,197.0	123.7
2021-12-31	1,040.4	2,401.5	130.0
2022-12-31	1,543.8	3,132.8	128.6
2023-12-31	1,722.3	2,409.5	127.8
2024-12-31	1,888.3	2,378.6	124.2
2025-12-31	2,203.2	3,478.7	122.7

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How profit was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

Figures behind the shape

Growth

31.2%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate31.2%
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
Five-year EPS growth rate21.9%
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
One-year change in net income46.3%
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Returns on capital

12.8%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital12.8%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity10.4%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets7.7%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

46.0%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin46.0%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin30.5%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin22.5%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin12.8%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

34.9x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings34.9x
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
Price to book3.6x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA19.5x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio7.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

0.07

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.07
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.14
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage47.6x
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score10.99
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.